Clinical and Translational Science Institute

Projects

Projects per year 2012 2015 2016 2017 2018 2019 2035

• 93 Active
• 217 Finished

Projects per year

Search results

• Finished

  A phase 3 open label, randomized, multicenter study of N

  Potter, D. A.

  NEKTAR THERAPEUTICS

  11/1/16 → 11/30/22

  Project: Research project

  • Label 100%

• A Randomized, Double Blind Phase 3 Study of Ibrutinib in

  Arora, M.

  PHARMACYCLICS, INC.

  11/1/16 → 11/30/22

  Project: Research project

  • Amaurosis 100%
  • Corticosteroid 100%
  • Ibrutinib 100%
  • Chronic Graft Versus Host Disease 50%
  • Placebo 50%

• A Phase I, Multicenter, Open-label, safety of Human Cord

  McClune, B. L.

  CELGENE CORPORATION

  10/20/16 → 12/31/20

  Project: Research project

  • Natural Killer Cell 100%
  • Multiple Myeloma 100%
  • Stem Cell Transplant 100%

• Prevention of Non-surgical bleeding by management of Hea

  Cogswell, R. J.

  ST. JUDE MEDICAL, INC.

  10/15/16 → 10/30/21

  Project: Research project

  • Operative Blood Loss 100%
  • Combination Therapy 50%
  • Patient 50%
  • Antiplatelet 50%

• Open label Dose Escalation Trial of an Adaptive Natural

  Janakiram, M.

  FATE THERAPEUTICS, INC.

  10/1/16 → 7/31/21

  Project: Research project

  • Natural Killer Cell 100%
  • Acute Myeloid Leukemia 100%
  • Infusion 100%
  • Adult 100%

• An Open-Label Extension Study of Inhaled Treprostinil in

  Thenappan, T.

  UNITED THERAPEUTICS CORPORATION

  10/1/16 → 10/30/21

  Project: Research project

  • Treprostinil 100%

• University of Pittsburgh Clinical and Translational Scie

  Johnson, S. & AbuSalah, A. M.

  UNIVERSITY OF PITTSBURGH, NATIONAL INSTITUTES OF HEALTH (NIH)

  10/1/16 → 5/31/21

  Project: Research project

  • Clinical and Translational Science 100%

• A Multi-Center Randomized double blind placebo controlle

  Thenappan, T.

  UNITED THERAPEUTICS CORPORATION

  10/1/16 → 10/30/21

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Pulmonary Hypertension 50%
  • Treprostinil 50%
  • Lung Disease 50%

• HM2016-25 A Phase 2 Study of the Safety, Tolerability, a

  Afrin, L. B.

  INCYTE CORPORATION

  9/28/16 → 6/12/18

  Project: Research project

  • Tolerability 100%
  • Myelofibrosis 50%
  • Ruxolitinib 50%

• A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women withMammographically Dense Breast

  Beckwith, H. C.

  UNIVERSITY OF TEXAS AT HOUSTON, NIH NATIONAL CANCER INSTITUTE (NCI)

  9/19/16 → 9/18/21

  Project: Research project

  • Placebo-Controlled Study 100%
  • Afimoxifene 100%
  • Blindness 100%

• A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast

  Beckwith, H. C.

  UNIV. OF TX M.D. ANDERSON CANCER CENTER, NIH NATIONAL CANCER INSTITUTE (NCI)

  9/19/16 → 9/18/21

  Project: Research project

  • Placebo-Controlled Study 100%
  • Afimoxifene 100%
  • Blindness 100%

• Ofatumumab in Combination with Glucocorticoids for Prima

  Arora, M.

  H. LEE MOFFITT CANCER CENTER & RESEARCH, NOVARTIS PHARMACEUTICALS CORPORATION

  9/1/16 → 6/30/22

  Project: Research project

  • Glucocorticoid 100%
  • Ofatumumab 100%
  • Host 50%

• Process for Collection of Stool Samples for Full-Spectru

  Khoruts, A. & Vaughn, B. P.

  CRESTOVO LLC

  9/1/16 → 7/2/19

  Project: Research project

  • Production 100%
  • Spectra 100%

• CITN-09: A Phase II Study of MK-3475 in Patients with Ad

  Domingo-Musibay, E.

  FRED HUTCHINSON CANCER CENTER, MERCK

  9/1/16 → 4/11/17

  Project: Research project

  • Inpatient 100%
  • Merkel Cell Carcinoma 100%

• A Phase 1b/2, Open-label, Multicenter, Dose-escalation a

  Domingo-Musibay, E.

  DYNAVAX TECHNOLOGIES CORPORATION

  9/1/16 → 11/30/18

  Project: Research project

  • Metastatic Melanoma 100%
  • Pembrolizumab 100%

• Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect

  Hui, J.

  UNIVERSITY OF WISCONSIN-MADISON, NIH NATIONAL CANCER INSTITUTE (NCI)

  8/12/16 → 9/23/21

  Project: Research project

  • Early Stage 100%

• Phase 2 Study of Brentuximab Vedotin And Bevacizumab In

  Gupta, S.

  SEAGEN INC

  8/1/16 → 7/31/22

  Project: Research project

  • Brentuximab Vedotin 100%
  • Bevacizumab 100%
  • Germinoma 50%

• Phase II Multicenter Trial of Single Autologous Hematopo

  Weisdorf, D. J. & Arora, M.

  NATIONAL MARROW DONOR PROGRAM

  8/1/16 → 8/31/22

  Project: Research project

  • Multiple Myeloma 100%
  • Transplantation 100%
  • Hematopoietic Cell 100%
  • Myeloma 100%
  • Dendritic Cell 100%

• METIS: Pivotal, open-label, randomized study of radiosur

  Lou, E.

  NOVOCURE INC.

  8/1/16 → 8/31/21

  Project: Research project

  • Brain Metastasis 100%
  • Non Small Cell Lung Cancer 100%
  • Neoplasm 100%

• Vertex Transferred Drug and study Sponsorship to Merck S

  Kratzke, R. A.

  VERTEX PHARMACEUTICALS INCORPORATED

  7/15/16 → 6/30/20

  Project: Research project

  • Drug 100%
  • Tolerability 50%
  • Human Study 50%
  • Solid Malignant Neoplasm 50%
  • Cytotoxic Chemotherapy 50%

• Influenza Vaccine to Effectively Stop Cardio Thoracic Ev

  Cogswell, R. J.

  UNIVERSITY OF WISCONSIN-MADISON, NIH NAT'L HEART, LUNG, AND BLOOD INSTITU

  7/1/16 → 1/31/17

  Project: Research project

  • Influenza Vaccine 100%

• A randomized, open-label, active-controlled, Phase II st

  Kratzke, R. A.

  BAYER HEALTHCARE PHARMACEUTICALS

  7/1/16 → 11/30/16

  Project: Research project

  • Mesothelin 100%
  • Growth Hormone 100%
  • Pleura Mesothelioma 100%
  • Vinorelbine 100%
  • Inpatient 100%

• A Phase 1 Study of the Clinical and Immunologic

  Holtan, S. G.

  FRED HUTCHINSON CANCER CENTER, ALTOR BIOSCIENCE LLC

  7/1/16 → 12/31/19

  Project: Research project

  • Cells 100%
  • Interleukin 15 50%
  • Head and Neck Cancer 50%
  • Lung 50%
  • Inpatient 50%

• A Multi-center, Open Label, Randomized Phase 2 Study of

  Gupta, S.

  ASTELLAS PHARMA, INC

  6/1/16 → 12/31/17

  Project: Research project

  • Kidney Metastasis 100%
  • Axitinib 100%

• A Randomized, Double-Blinded Phase II Study of Maintenan

  Rao, A. & Gupta, S.

  HOOSIER CANCER RESEARCH NETWORK, INC, MERCK AND CO INC

  6/1/16 → 5/31/21

  Project: Research project

  • Chemotherapy 100%
  • Placebo 100%
  • Urothelial Cancer 100%
  • Pembrolizumab 100%
  • Inpatient 100%

• A Single Cohort Phase 2 Study of Ruxolitinib in Combinat

  Rashidi, A.

  INCYTE CORPORATION

  6/1/16 → 10/30/21

  Project: Research project

  • Ruxolitinib 100%
  • Corticosteroid 50%
  • Steroids 50%
  • Acute Graft Versus Host Disease 50%

• Phase I/2 of INCB057643 in Advanced Malignancies

  Ryan, C. & Gupta, S.

  INCYTE CORPORATION

  5/26/16 → 9/30/20

  Project: Research project

• Multicenter Expanded Access Protocol of Allogeneic Epste

  Bachanova, V. & Lazaryan, A.

  ATARA BIOTHERAPEUTICS, INC

  5/20/16 → 1/1/22

  Project: Research project

  • Patient 100%
  • Cytotoxic T-Cell 50%
  • Lymphoma 50%
  • Lymphoproliferative Disease 50%
  • Epstein-Barr Virus 50%

• A Phase I Trial Testing NAM Expanded Haploidentical or M

  Bachanova, V.

  GAMIDA CELL LTD.

  5/9/16 → 11/30/23

  Project: Research project

  • Phase I Trials 100%
  • Multiple Myeloma 50%
  • Natural Killer Cell 50%
  • Donor 50%
  • Non-Hodgkin Lymphoma 50%

• Immune Monitoring During ASP2215 Therapy in Relapsed/Ref

  He, F. & Ustun, C.

  ASTELLAS PHARMA US, INC

  5/1/16 → 3/31/21

  Project: Research project

  • Immunity 100%
  • Myeloid 50%

• A US Multi-Site Observational Study in Patients with Unr

  Domingo-Musibay, E.

  BRISTOL-MYERS SQUIBB COMPANY

  5/1/16 → 6/30/21

  Project: Research project

  • Observational Study 100%

• A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Co

  Patel, M. R.

  MIRATI THERAPEUTICS, INC.

  4/30/16 → 12/31/20

  Project: Research project

  • Mocetinostat 100%
  • Histone Deacetylase Inhibitor 100%
  • Inhibitor 100%
  • Solid Malignant Neoplasm 50%
  • Durvalumab 50%

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled,

  Greeno, E. W.

  HALOZYME, INC

  4/28/16 → 5/31/21

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Paclitaxel 50%
  • Gemcitabine 50%
  • Recombinant Hyaluronidase 50%

• A Phase 3, Multicenter, Multinational, Randomized, Open-

  Ryan, C. & Gupta, S.

  PFIZER, INC.

  4/21/16 → 12/31/22

  Project: Research project

  • Avelumab 100%
  • Study Arm 100%

• MT2016-10 :A Phase 2a, Dose-Escalation, Open-Label Study

  Arora, M. & Lazaryan, A.

  KADMON CORPORATION, LLC

  4/20/16 → 10/31/22

  Project: Research project

  • Tolerability 100%
  • Chronic Graft Versus Host Disease 100%

• Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up

  Bachanova, V.

  NOVARTIS PHARMACEUTICALS CORPORATION

  4/1/16 → 9/30/23

  Project: Research project

  • Cell Therapy 100%
  • CD19 100%

• A Long-Term Outcomes Study to Assess STatin Residual Ris

  Duprez, D.

  ASTRAZENECA

  2/1/16 → 6/30/21

  Project: Research project

  • Statin 100%
  • Hypertriglyceridemia 50%
  • Patient 50%
  • Risk Reduction 50%
  • Cardiovascular Risk 50%

• A Phase IB/II study of nivolumab in combination with ALT

  Patel, M. R.

  MEDICAL UNIVERSITY OF SOUTH CAROLINA, ALTOR BIOSCIENCE LLC

  2/1/16 → 10/31/23

  Project: Research project

  • Nivolumab 100%

• A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMA

  Patel, M. R.

  GENENTECH, INC.

  2/1/16 → 12/31/20

  Project: Research project

  • Atezolizumab 100%
  • Carboplatin 100%
  • Pemetrexed 100%
  • Cisplatin 100%
  • Antibody 50%

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled

  Greeno, E. W.

  ASTELLAS PHARMA, INC

  2/1/16 → 2/28/21

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Placebo-Controlled Study 50%
  • Liver Cell Carcinoma 50%
  • Enzalutamide 50%

• A Phase 1/2 Open-Label Study to Evaluate the Safety, Tol

  Potter, D. A.

  INNOCRIN PHARMACEUTICALS, INC

  2/1/16 → 5/22/19

  Project: Research project

  • Tolerability 100%
  • Breast Cancer 100%
  • Pharmacodynamics 100%
  • Pharmacokinetics 100%

• Phase 2 Randomized, Double-Blinded, Controlled Study of

  Potter, D. A.

  CASCADIAN THERAPEUTICS, INC.

  1/26/16 → 7/13/18

  Project: Research project

  • Breast Carcinoma 100%
  • Trastuzumab 100%
  • Capecitabine 100%
  • Inpatient 100%
  • Placebo 100%

• A Phase 3 Randomized, Open-Label Study comparing Pexa-Ve

  Greeno, E. W.

  SILLAJEN USA, INC.

  1/1/16 → 9/30/20

  Project: Research project

  • Sorafenib 100%
  • Virus 50%
  • Thymidine Kinase 50%
  • Vaccinia 50%
  • Pexastimogene Devacirepvec 50%

• A Phase III, International, Randomized, Controlled Study

  Warlick, E. D.

  ONCONOVA THERAPEUTICS, INC.

  12/31/15 → 7/1/21

  Project: Research project

  • Rigosertib 100%
  • Myelodysplastic Syndrome 100%
  • Hypomethylating Agent 100%
  • Physician 100%
  • Therapeutic Procedure 100%

• A Phase 1/2 study of Vadastuximb Talirine (SGN-CD33A) in

  Warlick, E. D.

  SEAGEN INC

  12/30/15 → 12/30/21

  Project: Research project

  • Talirine 100%
  • Azacitidine 50%
  • Myelodysplastic Syndrome 50%

• A Phase 1, Multicenter, Open Label, Dose Escalating, Saf

  Cooley, S. A.

  CELGENE CORPORATION

  12/1/15 → 12/31/20

  Project: Research project

  • Label 100%
  • Dose 100%
  • Cord 50%
  • Safety 50%
  • Natural Killer Cell 50%

• An Open-label, Randomized Phase 3 Efficacy Study of ASP8

  Fujioka, N.

  ASTELLAS PHARMA, INC

  12/1/15 → 12/31/20

  Project: Research project

  • Efficacy Study 100%
  • Gefitinib 50%
  • Naquotinib 50%
  • Erlotinib 50%
  • Non Small Cell Lung Cancer 50%

• A Phase IB Study of Crizotinib in Combi

  Kratzke, R. A.

  PFIZER, INC.

  11/20/15 → 7/30/20

  Project: Research project

  • Crizotinib 100%
  • Pembrolizumab 50%
  • Non Small Cell Lung Cancer 50%

• A Phase III, Randomized, Open-label, Controlled, Multi-C

  Gupta, S.

  ASTRAZENECA

  11/15/15 → 4/1/19

  Project: Research project

  • Durvalumab 100%
  • Monotherapy 50%
  • Tremelimumab 50%
  • Chemotherapy 50%

• Outcomes AlloMap Registry (OAR) Study

  Missov, E.

  CAREDX, INC.

  10/1/15 → 8/31/18

  Project: Research project